Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Tomoya Yokota, Nobutoshi Ando, Hiroyasu Igaki, Masayuki Shinoda, Ken Kato, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yuukou Kitagawa

研究成果: Article

21 引用 (Scopus)

抜粋

Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

元の言語English
ページ(範囲)143-151
ページ数9
ジャーナルOncology (Switzerland)
89
発行部数3
DOI
出版物ステータスPublished - 2015 8 21

    フィンガープリント

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015). Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology (Switzerland), 89(3), 143-151. https://doi.org/10.1159/000381065